Global Health

Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety

Howard Mayer

Mark Wainberg

HOWARD MAYER, Pfizer Global Research, New London CT
MARK WAINBERG, McGill University, Montreal

Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
In a population of treatment-experienced HIV-infected subjects, maraviroc plus optimised background antiretroviral therapy provided significantly superior virologic control and increases in CD4 cell counts compared with placebo plus optimized background therapy. There were no clinically relevant differences in the safety profiles between the maraviroc and the placebo treatment groups. These drugs do not attack the virus itself but rather block host cells’ CCR5 cell surface cytokine receptors that HIV interacts with to gain entry into the cell. At the Los Angeles conference Dan Keller heard about the studies from Howard Mayer and Mark Wainberg.

Similar Interviews

  • Audio Journal of Global Health Issues: Good Adherence to HIV Antiretroviral Therapy in Rural Uganda">Audio Journal of Global Health Issues: Good Adherence to HIV Antiretroviral Therapy in Rural Uganda
  • PAUL WEIDLE, Centers for Disease Control and Prevention, Atlanta REFERENCE: Lancet 2006; 368:1587-94 In rural sub-Saharan Africa there are many barriers to

  • Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation
  • CHLOE THIO, Johns Hopkins University School of Medicine REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February

  • Audio Journal of Global Health Issues: Chloroquine for Malaria: Could It Make a Comeback?">Audio Journal of Global Health Issues: Chloroquine for Malaria: Could It Make a Comeback?
  • CHRIS PLOWE, University of Maryland School of Medicine, Baltimore REFERENCE: N Engl J Med 2006; 355:1955-66 In Malawi chloroquine was taken out

    Post a comment

    Subscribe to Audio Medica Podcast